A detailed history of Meeder Asset Management Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Meeder Asset Management Inc holds 76 shares of CRNX stock, worth $4,008. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76
Holding current value
$4,008
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$43.83 - $54.98 $3,331 - $4,178
76 New
76 $3,000
Q4 2021

Feb 11, 2022

SELL
$19.35 - $28.41 $38,467 - $56,479
-1,988 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$16.88 - $25.23 $33,557 - $50,157
1,988 New
1,988 $42,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.83B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.